Similarly, the disease phenotypes in TSC patient-derived PCs including abnormal differentiation, synaptic dysfunction and hypoexcitability, could be rescued by treatment with the mTOR inhibitor rapamycin (Sundberg et al., 2018). This evidence concerns the gene MTOR and tuberous sclerosis.